Cargando…
Case report: Rechallenge with EGFR–TKIs after immunotherapy in EGFR–mutated non–small cell lung cancer with leptomeningeal metastasis
Rechallenge of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) after PD-1 blockade failure was an effective therapy for non-small cell lung cancer (NSCLC) patients with resistance to EGFR-TKIs. The third-generation TKIs, like osimertinib and furmonertinib, can reach higher co...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705570/ https://www.ncbi.nlm.nih.gov/pubmed/36457498 http://dx.doi.org/10.3389/fonc.2022.957661 |
_version_ | 1784840313588678656 |
---|---|
author | Qian, Chunfa Zhang, Yuhai Cheng, Wanwan Zhang, Qingchao Li, Mengzhen Fang, Shencun |
author_facet | Qian, Chunfa Zhang, Yuhai Cheng, Wanwan Zhang, Qingchao Li, Mengzhen Fang, Shencun |
author_sort | Qian, Chunfa |
collection | PubMed |
description | Rechallenge of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) after PD-1 blockade failure was an effective therapy for non-small cell lung cancer (NSCLC) patients with resistance to EGFR-TKIs. The third-generation TKIs, like osimertinib and furmonertinib, can reach higher concentration in the cerebrospinal fluid (CSF) than other TKIs, and exhibit a beneficial effect in NSCLC patients with leptomeningeal metastases (LM) harboring sensitive EGFR mutation. Here, we report that two-stage IV pulmonary adenocarcinoma patients with LM harboring an EGFR L858R mutation benefit from the third-generation EGFR-TKIs rechallenge after immune checkpoint inhibitor (ICI) and anti-angiogenic agent combination therapy. Complete response (CR) to partial response (PR) of central nervous system (CNS) response was achieved immediately after the administration of furmonertinib and osimertinib. We conducted next-generation sequencing (NGS) and IHC to elucidate the evolution of driver mutations and the immune microenvironment. In conclusion, these two cases might provide a therapeutic strategy for further clinical practice. More research was needed to elucidate the resistance mechanisms and improve current treatment strategies in EGFR-mutated patients with LM. |
format | Online Article Text |
id | pubmed-9705570 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97055702022-11-30 Case report: Rechallenge with EGFR–TKIs after immunotherapy in EGFR–mutated non–small cell lung cancer with leptomeningeal metastasis Qian, Chunfa Zhang, Yuhai Cheng, Wanwan Zhang, Qingchao Li, Mengzhen Fang, Shencun Front Oncol Oncology Rechallenge of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) after PD-1 blockade failure was an effective therapy for non-small cell lung cancer (NSCLC) patients with resistance to EGFR-TKIs. The third-generation TKIs, like osimertinib and furmonertinib, can reach higher concentration in the cerebrospinal fluid (CSF) than other TKIs, and exhibit a beneficial effect in NSCLC patients with leptomeningeal metastases (LM) harboring sensitive EGFR mutation. Here, we report that two-stage IV pulmonary adenocarcinoma patients with LM harboring an EGFR L858R mutation benefit from the third-generation EGFR-TKIs rechallenge after immune checkpoint inhibitor (ICI) and anti-angiogenic agent combination therapy. Complete response (CR) to partial response (PR) of central nervous system (CNS) response was achieved immediately after the administration of furmonertinib and osimertinib. We conducted next-generation sequencing (NGS) and IHC to elucidate the evolution of driver mutations and the immune microenvironment. In conclusion, these two cases might provide a therapeutic strategy for further clinical practice. More research was needed to elucidate the resistance mechanisms and improve current treatment strategies in EGFR-mutated patients with LM. Frontiers Media S.A. 2022-11-15 /pmc/articles/PMC9705570/ /pubmed/36457498 http://dx.doi.org/10.3389/fonc.2022.957661 Text en Copyright © 2022 Qian, Zhang, Cheng, Zhang, Li and Fang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Qian, Chunfa Zhang, Yuhai Cheng, Wanwan Zhang, Qingchao Li, Mengzhen Fang, Shencun Case report: Rechallenge with EGFR–TKIs after immunotherapy in EGFR–mutated non–small cell lung cancer with leptomeningeal metastasis |
title | Case report: Rechallenge with EGFR–TKIs after immunotherapy in EGFR–mutated non–small cell lung cancer with leptomeningeal metastasis |
title_full | Case report: Rechallenge with EGFR–TKIs after immunotherapy in EGFR–mutated non–small cell lung cancer with leptomeningeal metastasis |
title_fullStr | Case report: Rechallenge with EGFR–TKIs after immunotherapy in EGFR–mutated non–small cell lung cancer with leptomeningeal metastasis |
title_full_unstemmed | Case report: Rechallenge with EGFR–TKIs after immunotherapy in EGFR–mutated non–small cell lung cancer with leptomeningeal metastasis |
title_short | Case report: Rechallenge with EGFR–TKIs after immunotherapy in EGFR–mutated non–small cell lung cancer with leptomeningeal metastasis |
title_sort | case report: rechallenge with egfr–tkis after immunotherapy in egfr–mutated non–small cell lung cancer with leptomeningeal metastasis |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705570/ https://www.ncbi.nlm.nih.gov/pubmed/36457498 http://dx.doi.org/10.3389/fonc.2022.957661 |
work_keys_str_mv | AT qianchunfa casereportrechallengewithegfrtkisafterimmunotherapyinegfrmutatednonsmallcelllungcancerwithleptomeningealmetastasis AT zhangyuhai casereportrechallengewithegfrtkisafterimmunotherapyinegfrmutatednonsmallcelllungcancerwithleptomeningealmetastasis AT chengwanwan casereportrechallengewithegfrtkisafterimmunotherapyinegfrmutatednonsmallcelllungcancerwithleptomeningealmetastasis AT zhangqingchao casereportrechallengewithegfrtkisafterimmunotherapyinegfrmutatednonsmallcelllungcancerwithleptomeningealmetastasis AT limengzhen casereportrechallengewithegfrtkisafterimmunotherapyinegfrmutatednonsmallcelllungcancerwithleptomeningealmetastasis AT fangshencun casereportrechallengewithegfrtkisafterimmunotherapyinegfrmutatednonsmallcelllungcancerwithleptomeningealmetastasis |